Rheumatology

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment (unless specifically indicated) and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.